SAN FRANCISCO, April 6, 2017 /PRNewswire/ -- Invitae
Corporation (NYSE: NVTA), one of the fastest growing genetic
information companies, today announced the launch of the Invitae
Patient Insights Network℠, a permission-based, patient-centered
network designed to make it easy for patients to share health
experiences, contribute de-identified clinical data, and maintain
their privacy while being connected to the latest research,
treatment, and disease education opportunities.
The Invitae Patient Insights Network (PIN) is a patient-directed
approach to the traditional patient registry. The Invitae PIN
enables patients with specific health conditions to share
information, be connected to clinical trial and research
opportunities, and contribute de-identified data across a wide
variety of health conditions. Registries have been shown to be very
valuable in advancing research in a number of diseases. The
information patients share can be used by clinicians, researchers,
and therapeutic developers to locate screened cohorts for possible
participation in research studies. Through the Invitae PIN,
patients direct and control how their de-identified information is
shared and can opt in or opt out at any time. In addition, Invitae
will continue to contribute de-identified data to public research
databases such as ClinVar, a freely available genetic information
database from the National Center for Biotechnology
Information.
"I have always believed that the answers we seek in our search
for a cure lie within the patient. Patients have long contributed
specimens for biological research, and now they can contribute
health information in real time, helping themselves and everyone
else who shares their diagnosis," said Bonnie Addario, founder and chair of the Bonnie
J. Addario Lung Cancer Foundation (ALCF). "Today we have
opportunities to understand and fight cancer like never before.
Patient insights networks can help further fuel progress while also
giving those living with cancer better understanding of their own
health. The path to better care begins and ends in the same place –
with patients."
Patients who enroll in the Invitae PIN are guided through a
series of questions to gather their diagnostic experience, genetic
information, treatment experience and other relevant health and
family history information. Based on their responses, patients gain
access to a dashboard that allows them to explore de-identified
information contributed by others with the same diagnosis, for
example viewing the treatment experiences of other breast cancer
patients. Using the dashboard, patients can manage their
preferences to share data or receive notifications about clinical
trials and research opportunities that match their profile. By
participating in the PIN and agreeing to share de-identified data,
patients build a powerful database that can help them better
understand their own health and significantly improve research
across heritable conditions.
"The Invitae Patient Insights Network has reimagined the
single-condition, often clinician-driven patient registry to
establish a multi-condition, patient-directed network. Patients who
participate in the Invitae PIN will have the ability to safely
store their information and direct how it is used. They can also
gain access to insights about how other patients with a similar
condition manage their health or connect to clinical trials and
other research opportunities," said Robert
Nussbaum, MD, chief medical officer of Invitae. "By
participating in the Invitae PIN, patients can also contribute to
research that will benefit everyone."
The Invitae PIN will open enrollment to people with a personal
or family history of cancer or who have had genetic testing for
cancer predisposition. Enrollment for patients with conditions in
additional clinical areas, such as cardiology and neurology, will
open throughout 2017. Patients, clinicians, researchers and
biopharma therapeutics developers interested in participating in
the Invitae Patient Insights Network can learn more and create an
account at pin.invitae.com.
"Knowing I can control my data and use it to see what has helped
other patients who are also battling lung cancer can help me make
decisions about my health," said Jim
Brown, a lung cancer survivor from Washington. "I choose to share my data in the
hopes that I am helping researchers develop treatments faster."
The Invitae PIN is established based on several important
principles: patients own and control their data; permission-based
sharing of patient data can be valuable to improving patient
outcomes; patients should decide what's best for them; and
technology can remove barriers to diagnosis and treatment.
Patients and clinicians interested in the Invitae Patient
Insights Network or genetic testing through Invitae should visit
the company's website at pin.invitae.com.
About Invitae
Invitae Corporation's (NYSE: NVTA) mission is to bring
comprehensive genetic information into mainstream medical practice
to improve the quality of healthcare for billions of people.
Invitae's goal is to aggregate most of the world's genetic tests
into a single service with higher quality, faster turnaround time,
and lower price than many single-gene and panel tests today. The
company currently provides a diagnostic service comprising hundreds
of genes for a variety of genetic disorders associated with
oncology, cardiology, neurology, pediatrics, and other rare disease
areas. Additionally, the company has created a Genome Network to
connect patients, clinicians, advocacy organizations, researchers,
and therapeutic developers to accelerate the understanding,
diagnosis, and treatment of hereditary disease. For more
information, visit our website at invitae.com.
Safe Harbor Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, including statements that the Invitae Patient Insights
Network can help patients better understand their own health and
significantly improve research across heritable conditions; and
that permission-based sharing of patient data can be valuable to
improving patient outcomes. Forward-looking statements are
subject to risks and uncertainties that could cause actual results
to differ materially, and reported results should not be considered
as an indication of future performance. These risks and
uncertainties include, but are not limited to: security breaches,
loss of data and other disruptions; laws and regulations applicable
to the company's business, including privacy laws; ethical and
social concerns related to the use of genetic information; and the
other risks set forth in the company's filings with the Securities
and Exchange Commission, including the risks set forth in the
company's Quarterly Report on Form 10-K for the year ended
December 31, 2016. These
forward-looking statements speak only as of the date hereof, and
Invitae Corporation disclaims any obligation to update these
forward-looking statements.
NOTE: Invitae and the Invitae logo are trademarks of Invitae
Corporation. All other trademarks and service marks are the
property of their respective owners.
Contact:
Laura D'Angelo
pr@invitae.com
314-920-0617
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/invitae-expands-its-genome-network-with-the-launch-of-the-invitae-patient-insights-network-pin-enabling-participants-to-share-health-information-and-contribute-to-research-300435766.html
SOURCE Invitae Corporation